Version June 2024
| Guideline-recommended therapy | Relative risk reductions in pivotal randomized clinical trial(s) (%) | Number needed to treat for mortality benefit (standardized to 12 m) | Relative risk reduction in meta-analysis |
| Angiotensin converting enzyme inhibitor OR angiotensin II receptor blocker | 17 | 77 | 20% |
| Beta-blocker therapy (carvedilol, bisoprolol, extended release metoprolol succinate) | 34 | 28 | 31% |
| Mineralocorticoid receptor antagonist | 30 | 18 | 25% |
| Hydralazine plus nitrate | 43 | 21 | Not available |
| Cardiac resynchronization therapy | 36 | 24 | 29/22% |
| Implantable cardioverter-defibrillator | 23 | 70 | 26% |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
